These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9861886)

  • 21. One pill, once daily: now an option for HIV patients.
    Sax PE
    AIDS Clin Care; 2006 Sep; 18(9):77. PubMed ID: 16995270
    [No Abstract]   [Full Text] [Related]  

  • 22. [Positive change from protease inhibitor to non-nucleoside reverse transcriptase inhibitor efavirenz. Improved virus control thanks to protease inhibitor switch].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():37-8. PubMed ID: 11373775
    [No Abstract]   [Full Text] [Related]  

  • 23. Four new antiretroviral medications will soon offer more options to HIV patients.
    Murphy MJ
    Fac Notes (New Orleans La); 1998; 10(4):1-3. PubMed ID: 11365545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. No more twice-a-day Crixivan.
    Vazquez E
    Posit Aware; 1998; 9(6):17. PubMed ID: 11366469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sparing the protease for some spoils the price for all.
    Grinberg L
    GMHC Treat Issues; 1998 Sep; 12(9):1-2. PubMed ID: 11365802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efavirenz dosing in patients receiving continuous ambulatory peritoneal dialysis.
    Gill MJ; Ostrop NJ; Fiske WD; Brennan JM
    AIDS; 2000 May; 14(8):1062-4. PubMed ID: 10853991
    [No Abstract]   [Full Text] [Related]  

  • 27. New once-daily HIV combination better tolerated.
    Expert Rev Anti Infect Ther; 2004 Dec; 2(6):826. PubMed ID: 15566325
    [No Abstract]   [Full Text] [Related]  

  • 28. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.
    DeJesus E; McCarty D; Farthing CF; Shortino DD; Grinsztejn B; Thomas DA; Schrader SR; Castillo SA; Sension MG; Gough K; Madison SJ;
    Clin Infect Dis; 2004 Aug; 39(3):411-8. PubMed ID: 15307010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose-ranging studies.
    Manion D
    Int J Clin Pract Suppl; 1999 Jun; 103():8-9. PubMed ID: 10622036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use.
    Moyle GJ; Wilkins E; Leen C; Cheesbrough A; Reynolds B; Gazzard BG
    AIDS; 2000 Jul; 14(10):1453-4. PubMed ID: 10930162
    [No Abstract]   [Full Text] [Related]  

  • 31. 48-week data released for combination treatment with efavirenz.
    AIDS Patient Care STDS; 1999 Jul; 13(7):438-40. PubMed ID: 10870602
    [No Abstract]   [Full Text] [Related]  

  • 32. Successful genotype-tailored treatment with small-dose efavirenz.
    Gatanaga H; Oka S
    AIDS; 2009 Jan; 23(3):433-4. PubMed ID: 19188761
    [No Abstract]   [Full Text] [Related]  

  • 33. Switching from protease inhibitors to the non-nuke efavirenz.
    TreatmentUpdate; 2001; 12(12):3. PubMed ID: 11570089
    [No Abstract]   [Full Text] [Related]  

  • 34. [3 years' data of tenofovir. Confirmed as a valuable building block].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():30-1. PubMed ID: 15373042
    [No Abstract]   [Full Text] [Related]  

  • 35. Some competition for 1592.
    GMHC Treat Issues; 1997; 11(4/5):10-1. PubMed ID: 11364373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Don't mix Sustiva with Fortovase.
    Posit Aware; 1998; 9(5):17. PubMed ID: 11365885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. No increase in CNS defects.
    AIDS Patient Care STDS; 2006 Oct; 20(10):732. PubMed ID: 17080576
    [No Abstract]   [Full Text] [Related]  

  • 38. [HIV infections: mortality reduced only in developed countries].
    Wehr A
    Dtsch Med Wochenschr; 1999 May; 124(18):A8-9. PubMed ID: 10356577
    [No Abstract]   [Full Text] [Related]  

  • 39. FDA notifications. Changes approved for Sustiva.
    AIDS Alert; 2002 Apr; 17(4):51. PubMed ID: 12030202
    [No Abstract]   [Full Text] [Related]  

  • 40. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
    Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
    Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.